Nan Fung Group Holdings Ltd Takes $4.49 Million Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Nan Fung Group Holdings Ltd purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 664,610 shares of the company's stock, valued at approximately $4,493,000. Recursion Pharmaceuticals comprises about 3.8% of Nan Fung Group Holdings Ltd's portfolio, making the stock its 10th biggest position. Nan Fung Group Holdings Ltd owned approximately 0.17% of Recursion Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Recursion Pharmaceuticals by 40.1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after purchasing an additional 9,737,196 shares in the last quarter. Geode Capital Management LLC lifted its position in Recursion Pharmaceuticals by 12.1% in the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock valued at $41,160,000 after acquiring an additional 655,238 shares during the last quarter. Norges Bank acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at $23,429,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Recursion Pharmaceuticals by 17.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock worth $15,372,000 after purchasing an additional 333,323 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Recursion Pharmaceuticals by 6.1% during the third quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock worth $7,751,000 after purchasing an additional 67,464 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RXRX. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Morgan Stanley reduced their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Finally, Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $8.20.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded up $0.14 during midday trading on Wednesday, hitting $5.77. The stock had a trading volume of 16,774,422 shares, compared to its average volume of 12,143,003. The company has a market capitalization of $2.32 billion, a PE ratio of -3.77 and a beta of 1.00. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The stock has a 50 day moving average price of $6.50 and a two-hundred day moving average price of $6.79. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million for the quarter, compared to analysts' expectations of $19.04 million. During the same period last year, the company posted ($0.42) earnings per share. The business's quarterly revenue was down 57.8% on a year-over-year basis. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.